X4 Pharmaceuticals (XFOR) Expected to Release Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.19) per share and revenue of $2.42 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The firm had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $4.29 on Wednesday. The company’s 50-day moving average price is $4.01 and its two-hundred day moving average price is $3.93. The firm has a market cap of $404.63 million, a P/E ratio of -0.94 and a beta of 0.37. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.83.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares of the company’s stock, valued at approximately $714,615. The trade was a 4.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.13% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of X4 Pharmaceuticals during the third quarter worth $47,000. Squarepoint Ops LLC bought a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth $50,000. Stifel Financial Corp acquired a new position in shares of X4 Pharmaceuticals during the fourth quarter worth $82,000. Finally, Virtu Financial LLC acquired a new position in shares of X4 Pharmaceuticals during the fourth quarter worth $90,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

XFOR has been the topic of several analyst reports. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.70.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.